Implication of arylamine N-acetyltransferase (NAT2) polymorphism on levels of tumour markers CEA, AFP, CA 125, CA 19.9, and CA 15.3

Reference

• AGUNDEZ, J. A. G., OLIVERA, M., LADERO, J. M., LESCUR, A. R., LEDESMA, M. C., RUBIO, M. D., MEYER, U. A. and BENITEZ, J. 1996, Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmaco genetics, 6, 501–512.
   Google Scholar
• AMBROSONE, C. B., FREUDENHEIM, J. L., GRAHAM, S., MARSHALL, J. R., VENA J. E., BRASURE, J. R., MICHALEK, A. M., LAUGHLIN, R., NEMOTO, T., GILLEN WATER, K. A. and SHIELDS, P. G. 1996, Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. Journal of the American Medical Association, 276, 1474–1501.
   Google Scholar
• AYNACIOGLU, A. S., CASCORBI, I., MROZIKIEWICZ, P. M. and ROOTS, I. 1997, Arylamine N- acetyltransf erase (NAT2) genotypes in a Turkish population. Pharmacogenetics, 7,327-331. BEGENT, R. 1984, The value of carcinoembryogenic antigen measurement in clinical practice. Annals of Clinical Biochemistry, 21,231–238.
   Google Scholar
• BROCKMOLLER, J., CASCORBI, I., KERB, R. and ROOTS, I. 1996, Combined analysis of inherited polymorphisms in arylamine N-acetyltransferasse 2, glutathione S-transferase M1 and Ti, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Research, 56, 3915–3925.
   PubMed Web of Science ®Google Scholar
• CAPORASO, N. and GOLDSTEIN, A. 1995, Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics, 5, 59–63.
   PubMedGoogle Scholar
• CAPORASO, N., LANDI, M. T.and VINEIS, P. 1991, Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics, 1, 4–19.
   Google Scholar
• CASCORBI, I., DRAKOULIS, N., BROCKMOLLER, J., MAURER, A., SPERLING, K. and ROOTS, I. 1995, Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. American Journal of Human Genetics, 57, 581–592.
   PubMed Web of Science ®Google Scholar
• CASCORBI, I., BROCKMOLLER, J., MROZIKIEWICZ, P. M., BAUER, S., LODDENKEMPER, R. and ROOTS, I. 1996, Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Research, 56,3961–3966.
   PubMed Web of Science ®Google Scholar
• COOPER, E. H., DE MELLO JR, J. P. and GILES, G. R. 1989, Biochemical markers in gastrointestinal malignancies. A rquivos de Gastroenterologia. 26, 131–140.
   PubMedGoogle Scholar
• EVANS, D. A. P. 1992, N-acetyltransferase. In Pharmacogenetics of Drug Metabolism, W. Kalow, ed. (New-York: Pergamon), pp. 95–178.
   Google Scholar
• GIL, J. P. and LECHNER, M. C. 1998, Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis, 19,37–41.
   PubMed Web of Science ®Google Scholar
• GONZALEZ, E J. and IDLE, J. R. 1994, Pharmacogenetic phenotyping and genotyping: present status and future potential. Clinical Pharmacokinetic. 26, 59–70.
   Google Scholar
• GRANT, D. M., TANG, B. K. and KALO WW. 1984, A simple test for acetylator phenotype using caffeine. British Journal of Clinical Pharmacology, 17,459–464.
   PubMed Web of Science ®Google Scholar
• HEIN, D. W. 1988, Acetylator genotype and arylamine- induced carcinogenesis. Biochimica et Biophysica Acta, 948,37–66.
   PubMed Web of Science ®Google Scholar
• HEIN, D. W., DOLL, M. A., RUSTAN, T. D., GRAY, K., FENG, Y, FERGUSON, R. J. and GRANT, D. M. 1993, Metabolic activation and deactivation of arylamine carcinogens by recombinant human NATI and polymorphic NAT2 acetyltransferases. Carcfriogenesis, 14,1633–1638.
   PubMed Web of Science ®Google Scholar
• HERBETH, B. and BAGREL, A. 1980, A study of factors influencing plasma CEA levels in an unselected population. Oncodevelopmental Biology and Medicine, 1,191–198.
   PubMedGoogle Scholar
• KINZLER, K. and VOGELSTEIN, B. 1995, Colorectal tumors. In The Metabolic and Molecular Basic of Inherited Disease, C. R. Scriver, A. L. Beaudet, W. S. Sly and D. Valle, eds (USA: Mc Graw - Hill), pp. 643–663.
   Google Scholar
• LANG, N. P, CHU, D. Z. J., HUNTER, C. E, KENDALL, D. C., FLAMMANG, T. J. and KADLUBAR, E E 1986, Role of aromatic amine acetyltransferase in human colorectal cancer. Archives of Surgery, 121,1259–1261.
   Google Scholar
• LUTZ, W., KRAJEWSKA, B. and PILACIK, B. 1997, Determination of tissue polypeptide antigens (TPA) and carcinoembryonic antigen (CEA) in serum: its value in the preliminary cancer risk assessment in asbestos exposed workers. International Journal of Occupational Medicine and Environmental Health, 10,259–265.
   PubMedGoogle Scholar
• MASHIMOTO, M., SUZUKI, T., ABE, M. and DEGUSHI, T. 1992, Molecular genotyping of N-acetylation polymorphism to predict phenotype. Human Genetics,90,139–143.
   PubMed Web of Science ®Google Scholar
• MROZIKIEWICZ, P. M., CASCORBI, I., BROCKMOLLER, J. and ROOTS, I. 1996, Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clinical Pharmacology and Therapeutics, 59,376–382.
   PubMed Web of Science ®Google Scholar
• VATSIS, K. R, WEBER, W. W., BELL, D. A., DUPRET, J. M., EVANS, D. A. P., GRANT, D. M., HEIN, D. W., Lug, H. J., MEYER, U. A., RELLING, M. V., SIM, E., Suzuki, T. and YAMAZOE, Y. 1995, Nomenclature for N-acetyltransferases. Pharmaco genetics, 5,1–17.
   Google Scholar
• WU, T. J. 1996, Diagnosis and management of cancer using serologic tumor markers. In Clinical Diagnosis and Management by Laboratory Methods, John Bernard Henry, ed. (Philadelphia: WB Saunders Co), pp. 1064–1080.
   Google Scholar